12th Annual Clinical Trials in CNS Conference

12th Annual Clinical Trials in CNS Conference

18-11-2013 - 19-11-2013 Marriott Hotel, Regents Park, London, UK

SMi is delighted to announce that its highly anticipated and respected 12th annual Clinical Trials in CNS Conference is coming to London.

SMi is delighted to announce that its highly anticipated and respected 12th annual Clinical Trials in CNS Conference is coming to London.

With an ever increasing average life expectancy neurodegenrative diseases are increasingly becoming more prevalent in society. With this comes a need for new and improved therapies for treating these neurodegenerative conditions. From Alzheimer’s to Parkinsons disease the target and mechanism by which a disease manifests is unique and presents challenges in how to approach such treatments, not to mention ethical and legal issues behind treatment and trial design.

Join SMi as we look at new approaches taken in this field towards a number of neurodegenerative disorders. From clinical trial modeling and simulation to the role of biomarkers, SMi takes a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This exciting conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials.

Benefits of Attending

Join SMi's fantastic forum for discussion where industry peers can discuss and debate a number of issues surrounding drug development in CNS disorders.

  • Discover through real life case studies how companies have managed clinical trials in a broad range of CNS diseases
  • Discuss latest technologies and advances in this area of research
  • Hear from industry leaders and learn about best practice applied to clinical trials in CNS
  • Evaluate the best approaches taken towards trial design and successful implementation of such trials
  • Learn about the latest drug developments targetted at CNS diseases

Company Spotlight

ImmunoGen

ImmunoGen

Acorda Therapeutics

Acorda_Therapeutics.jpg

US biotechnology company Acorda Therapeutics is focused on developing therapies for multiple sclerosis, spinal cord injury and other neurological conditions.

Back to top